image
Basic Materials - Agricultural Inputs - NASDAQ - US
$ 2.9
-21.4 %
$ 3.96 M
Market Cap
-0.47
P/E
1. INTRINSIC VALUE

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.[ Read More ]

The intrinsic value of one RKDA stock under the base case scenario is HIDDEN Compared to the current market price of 2.9 USD, Arcadia Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RKDA

image
FINANCIALS
5.33 M REVENUE
-46.46%
-13.9 M OPERATING INCOME
28.17%
-14 M NET INCOME
10.42%
-15.3 M OPERATING CASH FLOW
-9.42%
-4.34 M INVESTING CASH FLOW
-306.56%
5.51 M FINANCING CASH FLOW
21.97%
1.54 M REVENUE
17.69%
-1.76 M OPERATING INCOME
-88.89%
-2.4 M NET INCOME
-226.30%
-1.75 M OPERATING CASH FLOW
28.66%
180 K INVESTING CASH FLOW
-96.12%
4 K FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition Arcadia Biosciences, Inc.
image
Current Assets 15 M
Cash & Short-Term Investments 11.6 M
Receivables 514 K
Other Current Assets 2.82 M
Non-Current Assets 4.73 M
Long-Term Investments 0
PP&E 1.18 M
Other Non-Current Assets 3.56 M
Current Liabilities 3.59 M
Accounts Payable 801 K
Short-Term Debt 1.7 M
Other Current Liabilities 1.08 M
Non-Current Liabilities 3.41 M
Long-Term Debt 155 K
Other Non-Current Liabilities 3.26 M
EFFICIENCY
Earnings Waterfall Arcadia Biosciences, Inc.
image
Revenue 5.33 M
Cost Of Revenue 3.3 M
Gross Profit 2.03 M
Operating Expenses 16 M
Operating Income -13.9 M
Other Expenses 48 K
Net Income -14 M
RATIOS
38.09% GROSS MARGIN
38.09%
-261.50% OPERATING MARGIN
-261.50%
-262.31% NET MARGIN
-262.31%
-108.88% ROE
-108.88%
-70.95% ROA
-70.95%
-101.85% ROIC
-101.85%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Arcadia Biosciences, Inc.
image
Net Income -14 M
Depreciation & Amortization 984 K
Capital Expenditures -5 K
Stock-Based Compensation 717 K
Change in Working Capital -3.51 M
Others -3.12 M
Free Cash Flow -15.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Arcadia Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for RKDA of $6 , with forecasts ranging from a low of $6 to a high of $6 .
RKDA Lowest Price Target Wall Street Target
6 USD 106.90%
RKDA Average Price Target Wall Street Target
6 USD 106.90%
RKDA Highest Price Target Wall Street Target
6 USD 106.90%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Arcadia Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
2.88 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.44 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 01, 2024
Bought 1.44 K USD
Kawakami Mark
Chief Financial Officer
+ 700
2.06 USD
3 months ago
Aug 01, 2024
Bought 1.44 K USD
Schaefer Thomas J.
Chief Executive Officer
+ 700
2.06 USD
9 months ago
Feb 01, 2024
Bought 1.44 K USD
Schaefer Thomas J.
Chief Financial Officer
+ 700
2.06 USD
1 year ago
Aug 04, 2023
Bought 2.38 K USD
Schaefer Thomas J.
Chief Financial Officer
+ 649
3.67 USD
1 year ago
May 30, 2023
Bought 21.5 K USD
Jacot Stanley Jr
Chief Executive Officer
+ 5000
4.31 USD
1 year ago
Feb 01, 2023
Bought 161 USD
Schaefer Thomas J.
Chief Financial Officer
+ 700
0.23 USD
2 years ago
Aug 01, 2022
Bought 490 USD
Haley Pamela
Chief Financial Officer
+ 700
0.7 USD
4 years ago
Aug 03, 2020
Bought 1.85 K USD
Plavan Matthew T
Chief Executive Officer
+ 585
3.16 USD
4 years ago
Aug 03, 2020
Bought 2.21 K USD
Shultz Randall
Chief Technology Officer
+ 700
3.16 USD
4 years ago
Aug 03, 2020
Bought 2.21 K USD
Haley Pamela
Chief Financial Officer
+ 700
3.16 USD
4 years ago
Feb 03, 2020
Bought 1.2 K USD
Haley Pamela
Chief Financial Officer
+ 700
1.72 USD
4 years ago
Feb 03, 2020
Bought 1.2 K USD
Reiter Sarah
Chief Commercial Officer
+ 700
1.72 USD
4 years ago
Feb 03, 2020
Bought 1.2 K USD
Plavan Matthew T
Chief Executive Officer
+ 700
1.72 USD
4 years ago
Dec 23, 2019
Bought 5.36 K USD
Reiter Sarah
Chief Commercial Officer
+ 900
5.95 USD
5 years ago
Nov 19, 2019
Bought 4.52 K USD
Reiter Sarah
Chief Commercial Officer
+ 1000
4.52 USD
5 years ago
Nov 18, 2019
Bought 21.2 K USD
Murray Lilian Shackelford
Director
+ 5000
4.25 USD
5 years ago
Nov 14, 2019
Bought 4.08 K USD
Plavan Matthew T
Chief Executive Officer
+ 1000
4.0795 USD
5 years ago
Sep 23, 2019
Bought 10.5 K USD
Plavan Matthew T
Chief Executive Officer
+ 2000
5.25 USD
5 years ago
Sep 17, 2019
Bought 29.4 K USD
Comcowich Kevin
Director
+ 5000
5.8776 USD
5 years ago
Sep 10, 2019
Bought 6.52 K USD
Plavan Matthew T
Chief Executive Officer
+ 1000
6.5205 USD
5 years ago
Sep 10, 2019
Bought 6.49 K USD
Plavan Matthew T
Chief Executive Officer
+ 1000
6.493 USD
5 years ago
Sep 10, 2019
Bought 7.78 K USD
Reiter Sarah
Chief Commercial Officer
+ 1200
6.48 USD
5 years ago
Sep 10, 2019
Bought 64.9 K USD
Comcowich Kevin
Director
+ 10000
6.49 USD
5 years ago
Sep 10, 2019
Bought 32.4 K USD
Comcowich Kevin
Director
+ 5000
6.4866 USD
5 years ago
Aug 28, 2019
Bought 6.88 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
6.88 USD
5 years ago
Aug 27, 2019
Bought 17.9 K USD
Plavan Matthew T
Chief Financial Officer
+ 2000
8.93 USD
5 years ago
Aug 27, 2019
Bought 8.95 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
8.95 USD
5 years ago
Aug 27, 2019
Bought 9.3 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
9.3 USD
5 years ago
Aug 27, 2019
Bought 9.32 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
9.32 USD
5 years ago
Aug 26, 2019
Bought 9.22 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
9.22 USD
5 years ago
Aug 26, 2019
Bought 8.33 K USD
Plavan Matthew T
Chief Financial Officer
+ 1000
8.33 USD
6 years ago
Mar 23, 2018
Sell 167 K USD
Rey Eric J.
Director
- 5000
33.44 USD
6 years ago
Mar 23, 2018
Sell 57.3 K USD
Lu Zhongjin
VP Product Development
- 1750
32.74 USD
6 years ago
Mar 15, 2018
Sell 15 K USD
Rey Eric J.
Director
- 250
60 USD
6 years ago
Mar 14, 2018
Sell 950 K USD
Rey Eric J.
Director
- 21005
45.209 USD
7 years ago
Nov 17, 2017
Sell 1.36 K USD
Lu Zhongjin
VP Product Development
- 5950
0.228 USD
7 years ago
Jun 08, 2017
Bought 3.75 K USD
Rey Eric J.
Director
+ 5000
0.75 USD
8 years ago
Aug 04, 2016
Sell 251 USD
Salameh Roger
Chief Operating Officer
- 100
2.51 USD
8 years ago
Jun 13, 2016
Sell 20.6 K USD
Brandwein Steven F.
Interim Chief Financ. Officer
- 8280
2.4934 USD
8 years ago
Apr 25, 2016
Sell 4.17 K USD
Brandwein Steven F.
Interim Chief Financ. Officer
- 1720
2.424 USD
8 years ago
Apr 05, 2016
Sell 4.93 K USD
Knauf Vic C.
Chief Scientific Officer
- 1653
2.982 USD
8 years ago
Apr 04, 2016
Sell 3.57 K USD
Knauf Vic C.
Chief Scientific Officer
- 1200
2.975 USD
8 years ago
Mar 04, 2016
Sell 9.58 K USD
Knauf Vic C.
Chief Scientific Officer
- 2973
3.224 USD
8 years ago
Mar 03, 2016
Sell 891 USD
Knauf Vic C.
Chief Scientific Officer
- 300
2.97 USD
8 years ago
Feb 01, 2016
Sell 5 K USD
Knauf Vic C.
Chief Scientific Officer
- 1666
3.003 USD
8 years ago
Feb 01, 2016
Sell 8.79 K USD
Rey Eric J.
President and CEO
- 3000
2.9313 USD
8 years ago
Feb 03, 2016
Sell 556 USD
Rey Eric J.
President and CEO
- 200
2.78 USD
8 years ago
Dec 15, 2015
Sell 35.8 K USD
Brandwein Steven F.
Interim Chief Financ. Officer
- 10035
3.5663 USD
8 years ago
Dec 01, 2015
Sell 24.5 K USD
Knauf Vic C.
Chief Scientific Officer
- 6300
3.8889 USD
8 years ago
Dec 02, 2015
Sell 35.6 K USD
Knauf Vic C.
Chief Scientific Officer
- 8700
4.0959 USD
9 years ago
Nov 11, 2015
Sell 13.2 K USD
Knauf Vic C.
Chief Scientific Officer
- 4527
2.9138 USD
9 years ago
Oct 09, 2015
Sell 15.5 K USD
Rey Eric J.
President and CEO
- 5145
3.0066 USD
9 years ago
Oct 08, 2015
Sell 4.48 K USD
Rey Eric J.
President and CEO
- 1500
2.988 USD
9 years ago
Oct 07, 2015
Sell 10.5 K USD
Rey Eric J.
President and CEO
- 3500
3.0025 USD
9 years ago
Oct 06, 2015
Sell 13.4 K USD
Rey Eric J.
President and CEO
- 4100
3.2803 USD
9 years ago
Oct 05, 2015
Sell 44.5 K USD
Rey Eric J.
President and CEO
- 14136
3.1509 USD
9 years ago
Oct 02, 2015
Sell 8.66 K USD
Rey Eric J.
President and CEO
- 2900
2.9874 USD
9 years ago
Oct 01, 2015
Sell 13.2 K USD
Rey Eric J.
President and CEO
- 4600
2.8722 USD
9 years ago
Sep 30, 2015
Sell 18.4 K USD
Rey Eric J.
President and CEO
- 5800
3.1697 USD
9 years ago
Sep 29, 2015
Sell 13.7 K USD
Rey Eric J.
President and CEO
- 3900
3.5173 USD
9 years ago
Sep 28, 2015
Sell 22.8 K USD
Rey Eric J.
President and CEO
- 6200
3.6854 USD
9 years ago
Sep 25, 2015
Sell 40.3 K USD
Rey Eric J.
President and CEO
- 10000
4.027 USD
9 years ago
Sep 24, 2015
Sell 30.7 K USD
Rey Eric J.
President and CEO
- 7089
4.3239 USD
9 years ago
Sep 23, 2015
Sell 19.2 K USD
Rey Eric J.
President and CEO
- 4000
4.8022 USD
9 years ago
Sep 14, 2015
Sell 3.31 K USD
Emlay Don
VP Regulatory and Compliance
- 689
4.8061 USD
9 years ago
Sep 11, 2015
Sell 11.2 K USD
Emlay Don
VP Regulatory and Compliance
- 2284
4.9181 USD
9 years ago
Sep 10, 2015
Sell 2.89 K USD
Emlay Don
VP Regulatory and Compliance
- 548
5.2708 USD
9 years ago
Sep 11, 2015
Sell 8.11 K USD
Salameh Roger
VP Business Development
- 1648
4.9181 USD
9 years ago
Sep 11, 2015
Sell 5.25 K USD
Lu Zhongjin
VP Product Development
- 1068
4.9181 USD
9 years ago
Sep 10, 2015
Sell 8.3 K USD
Salameh Roger
VP Business Development
- 1575
5.2708 USD
9 years ago
Sep 09, 2015
Sell 15.3 K USD
Salameh Roger
VP Business Development
- 2765
5.5458 USD
9 years ago
Sep 08, 2015
Sell 19.3 K USD
Salameh Roger
VP Business Development
- 3500
5.5089 USD
9 years ago
Sep 10, 2015
Sell 6.86 K USD
Lu Zhongjin
VP Product Development
- 1302
5.2708 USD
9 years ago
Sep 09, 2015
Sell 13.1 K USD
Lu Zhongjin
VP Product Development
- 2370
5.5458 USD
9 years ago
Sep 08, 2015
Sell 16.5 K USD
Lu Zhongjin
VP Product Development
- 3000
5.5089 USD
9 years ago
Sep 10, 2015
Sell 3.03 K USD
Knauf Vic C.
Chief Scientific Officer
- 575
5.2708 USD
9 years ago
Sep 09, 2015
Sell 15.3 K USD
Knauf Vic C.
Chief Scientific Officer
- 2765
5.5458 USD
9 years ago
Sep 08, 2015
Sell 19.3 K USD
Knauf Vic C.
Chief Scientific Officer
- 3500
5.5089 USD
9 years ago
May 20, 2015
Bought 3 M USD
Garg Uday
director, 10 percent owner:
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 3 M USD
Mandala Agribusiness Co-Investments I Ltd
10 percent owner
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 3 M USD
Mandala Agribusiness Co-Investments I Ltd
10 percent owner
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 3 M USD
Garg Uday
director, 10 percent owner:
+ 375000
8 USD
9 years ago
May 20, 2015
Bought 8 M USD
Shupp Darby E
director, 10 percent owner:
+ 1000000
8 USD
9 years ago
May 20, 2015
Bought 100 K USD
Reis James Richard
Director
+ 12500
8 USD
9 years ago
May 20, 2015
Bought 8 M USD
BISHOP TERRI C
10 percent owner
+ 1000000
8 USD
7. News
Arcadia Biosciences (RKDA) Reports Q3 Loss, Tops Revenue Estimates Arcadia Biosciences (RKDA) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $1.83 per share a year ago. zacks.com - 4 days ago
Arcadia Biosciences, Inc. (RKDA) Q3 2024 Earnings Call Transcript Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Operator Good afternoon, and welcome to Arcadia Biosciences Third Quarter 2024 Financial Results and Business Highlights Conference Call. seekingalpha.com - 4 days ago
Arcadia Biosciences (RKDA) Announces Date of Third Quarter 2024 Financial Results and Business Highlights Conference Call DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the third quarter of 2024 after market close on November 12, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss third-quarter results and key strategic achievements. Interested participants can join the conferenc. businesswire.com - 2 weeks ago
4 Agriculture - Products Stocks to Watch Despite Industry Concerns The near-term outlook for the Zacks Agriculture - Products industry is uncertain due to low commodity prices and inflated costs. Investors should watch BG, WFG, HYFM and RKDA, which are braving the industry headwinds. zacks.com - 3 weeks ago
Arcadia Biosciences (RKDA) Q2 Earnings Miss, Increase Y/Y Arcadia Biosciences (RKDA) witnesses a solid 42% improvement in Zola sales in Q2. The company continues to invest to grow the Zola brand through mass market retailers and grocery store chains. zacks.com - 3 months ago
Arcadia Biosciences, Inc. (RKDA) Q2 2024 Earnings Call Transcript Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Mark Kawakami - CFO T.J. Schaefer - President & CEO Conference Call Participants Raghuram Selvaraju - H.C. seekingalpha.com - 3 months ago
Arcadia Biosciences (RKDA) Q2 Earnings Miss Estimates Arcadia Biosciences (RKDA) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $1.27 per share. This compares to loss of $2.64 per share a year ago. zacks.com - 3 months ago
Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2024 Financial Results and Business Highlights DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the second quarter and first half of 2024. “The second quarter of 2024 was a significant turning point for Arcadia as we transform the business and chart our path to becoming cash flow positive,” said T.J. Schaefer, president and CEO. “We monetized our wheat IP through two transactions: selling. businesswire.com - 3 months ago
Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration LOS ANGELES--(BUSINESS WIRE)--Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration. businesswire.com - 3 months ago
Arcadia Biosciences (RKDA) Announces Date of Second Quarter 2024 Financial Results and Business Highlights Conference Call DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the second quarter and first half of 2024 after market close on August 13, 2024. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss second-quarter results and key strategic achievements. Interested participants can joi. businesswire.com - 3 months ago
Arcadia Biosciences (RKDA) Upgraded to Strong Buy: Here's What You Should Know Arcadia Biosciences (RKDA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 4 months ago
The Cheesecake Factory Offers Triple the Reasons to Celebrate National Cheesecake Day This Year CALABASAS HILLS, Calif.--(BUSINESS WIRE)--The Cheesecake Factory® is celebrating its favorite holiday – National Cheesecake Day – in a big way this year making it a two-day celebration and introducing the newest flavor to its legendary lineup on July 29: Triple Berry Bliss Cheesecake – creamy cheesecake layered with vanilla cake, three kinds of berries and a kiss of citrus. For every slice of Triple Berry Bliss Cheesecake sold through July 29, 2025, The Cheesecake Factory will donate 25 cents t. businesswire.com - 4 months ago
8. Profile Summary

Arcadia Biosciences, Inc. RKDA

image
COUNTRY US
INDUSTRY Agricultural Inputs
MARKET CAP $ 3.96 M
Dividend Yield 0.00%
Description Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Contact 202 Cousteau Place, Davis, CA, 95618 https://www.arcadiabio.com
IPO Date May 15, 2015
Employees 21
Officers Mr. Mark Kawakami Chief Financial Officer